Utilizing HER2-targeted treatments in colorectal cancer

touchMDT for touchONCOLOGY Two medical oncologists discuss the latest clinical trial data for HER2-targeted treatments in colorectal cancer (CRC), how they utilize these agents in clinical practice, and what the future holds for HER2-targeting in CRC. The multidisciplinary team: Medical oncologists: Dr Kristen Ciombor, Nashville, TN, USA and Prof. Andrea Sartore-Bianchi, Milan, Italy This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Seagen Inc. and is jointly provided by USF Health and touchIME. For further information visit our website: https://touchoncologyime.org/mdt-perspectives-on-management-of-her2-crc/